{"id":483184,"date":"2020-05-07T22:30:02","date_gmt":"2020-05-07T22:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483184"},"modified":"2020-05-07T22:30:02","modified_gmt":"2020-05-07T22:30:02","slug":"benign-prostatic-hyperplasia-bph-epidemiology-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-epidemiology-forecast-2030_483184.html","title":{"rendered":"Benign prostatic hyperplasia (BPH) Epidemiology Forecast, 2030"},"content":{"rendered":"
\"Benign<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

DelveInsight’s ‘Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030<\/strong><\/a>‘ report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

The histologic Benign Prostatic Hyperplasia prevalence is approximately 10% for men in their 30s, 20% for men in their 40s, reaches 50% to 60% for men in their 60s, and is 80% to 90% for men in their 70s and 80s. Benign Prostatic Hyperplasia prevalence increases after the age of 40 years, with a prevalence of 8%–60% at age 90 years.<\/strong><\/p>\n

Scope of the Report<\/strong><\/p>\n